Skip to main content

Table 1 Experimental design of bleomycin sulfate (BS)-induced lung fibrosis in a 28-day rat model

From: Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis

Group ID Exposure N Bleomycin dose (mg/kg), Route Eso dose (mg/kg) Route Dosing days Necropsy day
1 Saline-vehicle control 6 0, IT Vehicle PO 10–28 28
2 BS control 10 ~4.0, IT Vehicle PO 10–28 28
3 BS + eso low therapeutic 10 ~4.0, IT 30 PO 10–28 28
4 BS + eso high therapeutic 10 ~4.0, IT 300 PO 10–28 28
5 BS + eso low prophylactic 15 ~4.0, IT 30 PO 2–28 28
6 BS + eso high prophylactic 15 ~4.0, IT 300 PO 2–28 28
7 BS + pirfenidone 10 ~4.0, IT 100 PO, BID 10–28 28
  1. Initially, the groups were exposed to normal saline or BS intra-tracheally (IT) and then received vehicle, esomeprazole (prophylactically or therapeutically) or therapeutic pirfenidone orally (PO) for the indicated course.
  2. N number of animals, BID twice daily, Eso esomeprazole.